Company
Headquarters: Chengdu, China
Employees: 211
CEO: Dr. Bo Chen
HK$18.37 Billion
HKD as of Jan. 1, 2026
US$2.36 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Keymed Biosciences Inc. engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its products include CM310 drug in patients with moderate to severe atopic dermatitis, asthma, chronic sinusitis with polyps, chronic obstructive pulmonary disease, etc.; IL-4Ra antibody approved for clinical trials; and CMG901, an antibody-drug approved for clinical trials in China and the United States. The company was formerly known as 2Health Biosciences, Inc. and changed its name to Keymed Biosciences Inc. The company was founded in 2016 and is headquartered in Chengdu, China.
Keymed Biosciences, Inc. has the following listings and related stock indices.
Stock: HKEX: 2162 wb_incandescent